Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Current Value
$94.821 Year Return
Current Value
$94.821 Year Return
Market Cap
$4.63B
P/E Ratio
-14.6
1Y Stock Return
61.30%
1Y Revenue Growth
51.47%
Dividend Yield
0.00%
Price to Book
49.8
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ALT | 40.84% | $531.30M | +194.09% | 0.00% |
CRNX | 39.76% | $5.12B | +84.27% | 0.00% |
PLRX | 39.50% | $778.32M | -9.55% | 0.00% |
TREE | 38.47% | $573.76M | +169.05% | 0.00% |
SDGR | 38.20% | $1.38B | -35.46% | 0.00% |
FUN | 37.22% | $4.60B | -16.51% | 0.00% |
NTLA | 36.38% | $1.44B | -50.35% | 0.00% |
MODG | 36.09% | $1.56B | -25.89% | 0.00% |
KFRC | 35.88% | $1.10B | -8.71% | 0.66% |
PGEN | 35.78% | $228.91M | -28.00% | 0.00% |
TFIN | 35.43% | $2.34B | +43.04% | 0.00% |
LAW | 35.15% | $325.90M | -3.37% | 0.00% |
KALV | 35.05% | $440.88M | +17.08% | 0.00% |
ORC | 34.75% | $615.55M | +6.95% | 18.46% |
SFBS | 34.69% | $5.11B | +85.58% | 1.29% |
ITCI | 34.55% | $8.84B | +42.41% | 0.00% |
RAPT | 34.52% | $37.41M | -92.14% | 0.00% |
FOLD | 34.51% | $2.84B | -11.52% | 0.00% |
HSTM | 34.49% | $980.58M | +26.38% | 0.43% |
FBRT | 34.37% | $1.06B | +0.23% | 10.99% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CYCN | -0.05% | $4.77M | -16.19% | 0.00% |
VZ | 0.06% | $176.51B | +12.56% | 6.37% |
X | 0.06% | $8.76B | +13.32% | 0.51% |
IHG | 0.06% | $19.32B | +55.71% | 1.30% |
DOGZ | 0.07% | $614.77M | +1,372.26% | 0.00% |
SBLK | -0.11% | $2.38B | +2.30% | 10.64% |
JBLU | 0.13% | $2.07B | +41.57% | 0.00% |
MCK | 0.13% | $78.15B | +35.51% | 0.42% |
BEST | -0.18% | $31.65M | +3.88% | 0.00% |
MNR | 0.19% | $1.66B | -10.71% | 15.90% |
HIHO | -0.19% | $8.63M | 0.00% | 6.12% |
GLP | 0.20% | $1.77B | +51.33% | 5.50% |
VNET | 0.21% | $954.90M | +33.82% | 0.00% |
ADM | -0.23% | $25.34B | -28.13% | 2.82% |
NLOP | 0.24% | $458.04M | +94.60% | 0.00% |
WM | 0.27% | $87.92B | +27.58% | 1.34% |
SPH | -0.27% | $1.15B | +6.07% | 7.25% |
WPRT | 0.28% | $76.83M | -36.88% | 0.00% |
RILY | 0.32% | $145.72M | -79.86% | 20.75% |
FINV | 0.34% | $909.61M | +27.93% | 3.80% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TCTM | -15.10% | $8.10M | -42.99% | 0.00% |
VZIO | -13.64% | $2.29B | +67.76% | 0.00% |
PULM | -10.88% | $19.83M | +202.98% | 0.00% |
DADA | -10.86% | $367.07M | -63.71% | 0.00% |
CANG | -10.43% | $253.50M | +212.50% | 0.00% |
FENG | -9.27% | $13.37M | +96.77% | 0.00% |
HUYA | -8.78% | $233.16M | +14.40% | 0.00% |
HUSA | -6.63% | $16.69M | -11.56% | 0.00% |
STG | -5.91% | $35.67M | +7.92% | 0.00% |
CNC | -5.79% | $29.19B | -21.56% | 0.00% |
LX | -5.70% | $446.80M | +57.07% | 4.21% |
NMM | -5.62% | $1.58B | +126.51% | 0.38% |
QNTM | -5.45% | $9.19M | -94.36% | 0.00% |
SKM | -5.21% | $8.53B | -0.67% | 6.32% |
MOMO | -5.00% | $909.44M | +4.43% | 0.00% |
KEP | -4.86% | $11.16B | +25.58% | 0.00% |
XOS | -4.81% | $30.51M | -57.24% | 0.00% |
NGL | -4.01% | $572.94M | +5.60% | 0.00% |
AIFU | -3.84% | $67.49M | -83.02% | 0.00% |
KSPI | -3.79% | $20.86B | +18.06% | 3.37% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 48.15% | $6.58B | 0.35% |
XPH | 47.84% | $157.87M | 0.35% |
PTH | 46.23% | $143.31M | 0.6% |
PBE | 44.49% | $258.53M | 0.58% |
IWC | 42.59% | $933.99M | 0.6% |
IBB | 41.72% | $6.66B | 0.45% |
GNOM | 40.51% | $70.59M | 0.5% |
IWO | 39.62% | $12.56B | 0.24% |
ZIG | 38.81% | $52.15M | 0.84% |
FBT | 38.58% | $1.11B | 0.56% |
VTWO | 38.52% | $12.38B | 0.1% |
ARKG | 38.33% | $1.13B | 0.75% |
BSVO | 38.22% | $1.53B | 0.47% |
IWM | 37.95% | $75.73B | 0.19% |
ISCG | 37.91% | $640.00M | 0.06% |
EDOC | 37.80% | $40.86M | 0.68% |
XHE | 37.79% | $213.41M | 0.35% |
FYX | 37.16% | $959.00M | 0.6% |
NUSC | 37.02% | $1.27B | 0.31% |
GSSC | 36.75% | $529.86M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
AGZD | -0.10% | $142.76M | 0.23% |
DBO | -0.62% | $217.57M | 0.77% |
DBE | -0.67% | $50.13M | 0.77% |
BTF | 0.79% | $51.69M | 1.24% |
MINT | 0.96% | $11.62B | 0.35% |
GCC | 1.14% | $133.23M | 0.55% |
HIGH | 1.47% | $302.78M | 0.51% |
SEIX | 1.60% | $268.81M | 0.62% |
COMT | 1.60% | $829.06M | 0.48% |
TPMN | 2.02% | $40.60M | 0.65% |
BOXX | -2.17% | $4.43B | 0.1949% |
BILZ | 2.19% | $563.02M | 0.14% |
GSG | 2.68% | $914.42M | 0.75% |
XBIL | -2.79% | $637.70M | 0.15% |
FBY | 2.86% | $127.69M | 0.99% |
FMF | 2.99% | $244.61M | 0.95% |
CLOI | 3.03% | $715.40M | 0.4% |
CORN | 3.08% | $61.12M | 0.2% |
WEAT | 3.32% | $120.27M | 0.28% |
BITO | 3.55% | $2.65B | 0.95% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -27.55% | $388.04M | 1.43% |
VIXY | -17.95% | $195.31M | 0.85% |
UUP | -17.60% | $309.25M | 0.77% |
DBA | -14.12% | $755.88M | 0.93% |
USDU | -14.06% | $201.97M | 0.5% |
TAIL | -7.55% | $67.98M | 0.59% |
TBIL | -7.42% | $4.38B | 0.15% |
CTA | -6.67% | $350.27M | 0.78% |
SGOV | -6.56% | $27.53B | 0.09% |
USCI | -6.23% | $185.47M | 1.07% |
EQLS | -4.63% | $76.08M | 1% |
KMLM | -4.53% | $353.87M | 0.9% |
HDRO | -4.07% | $164.26M | 0.3% |
XBIL | -2.79% | $637.70M | 0.15% |
BOXX | -2.17% | $4.43B | 0.1949% |
DBE | -0.67% | $50.13M | 0.77% |
DBO | -0.62% | $217.57M | 0.77% |
AGZD | -0.10% | $142.76M | 0.23% |
BTF | 0.79% | $51.69M | 1.24% |
MINT | 0.96% | $11.62B | 0.35% |
Yahoo
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
Yahoo
Q3 2024 Axsome Therapeutics Inc Earnings Call
Yahoo
AXSM earnings call for the period ending September 30, 2024.
Yahoo
Investors rally behind Axsome's explosive growth, with FDA approvals and breakthrough drugs driving momentum.
SeekingAlpha
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ETCompany ParticipantsDarren Opland - Director, Corporate...
SeekingAlpha
Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.